摘要
目的:观察国产吉西他滨(泽菲)联合顺铂治疗晚期非小细胞肺癌(NSCLC)的近期疗效及毒副反应。方法:有明确病理和/或细胞学诊断的晚期NSCLC病例30例,泽菲1.0g/m2,静脉滴注,d1、d8,顺铂80mg/m2,静脉滴注,d1,以21天为1周期,连用2个周期后评价疗效。结果:全组30例均可评价,CR 0,PR 13例,NC 9例,PD 7例。有效率为43.33%(13/30),主要毒副反应为胃肠反应和血液毒性,III^IV级白细胞和血小板下降分别为21.74%和16.67%。结论:泽菲联合顺铂治疗NSCLC有较好疗效,毒性较小可以耐受。
Objective： To evaluate effect of domestic gemcitabine （ZEFEI） plus cisplatin on non-small cell lung cancer（NSCLC）. Methods： Thirty cases of cytologically and pathologically confirmed adcanced NSCLC were treated with combined chemotherapy including domestic gemcitabine and cisplatin. Gemcitabinel.0g/m^2 IV, day 1 and day 8, cisplatin 80mg/m^2 IV dl ,a cycle was 21 days. Effect was eraluated after 2 cycles. Results： All cases were evaluated. There was no CR in patients treated with the regimen, PR 13, NC 9 cases, PD 7 cases. The response rate was 43.33% （13/30）. The side effects were mainly myleosuppression and digestive tract rection. Grade Ⅲ-Ⅳ leucoponia and thrombocytoponia were 21.74% and 16.67%. Conclusion：The combined chemotherapy is effective and safe in the treatment of advanced NSCLC and the adverse effects are tolerable.
出处
《现代肿瘤医学》
CAS
2006年第8期961-962,共2页
Journal of Modern Oncology
关键词
非小细胞肺癌
化疗
吉西他滨
顺铂
non-small cell lung cancer
chemotherapy
gemcitabine
cisplatin
